Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and Theravance have announced the regulatory submissions for furoate FF/vilanterol VI (FF/VI) to treat chronic obstructive pulmonary disease (COPD) in the US and Europe.
Subscribe to our email newsletter
The companies also announced regulatory submission for FF/VI as asthma therapy in the European Union.
FF/VI, which also includes the investigational LAMA/LABA combination umeclidinium bromide/vilanterol,VI monotherapy and MABA, was developed in collaboration with Theravance, as well as GSK’s investigational medicines FF monotherapy, UMEC monotherapy and anti-IL5 MAb.
A marketing authorisation application for FF/VI, with the proposed brand name Relvar, administered by a new dry powder inhaler called Ellipta, was submitted as asthma (100/25mcg and 200/25mcg) and COPD (100/25mcg) treatments in the Europe.
A new drug application for FF/VI, with the proposed brand name Breo, administered by the Ellipta inhaler, was submitted for FDA approval as COPD (100/25mcg) treatment.